Latest Medtech News
Wellvii announced FDA clearance for its BP Go blood pressure monitor, which uses a finger-based sensor to measure blood pressure rather than the traditional inflatable arm cuff, and is designed for home and remote-care monitoring settings.
BP Go runs on the same finger-based NIBP algorithm as Wellvii's earlier VitalDetect device, a 9-in-1 vital signs monitor that received FDA 510(k) clearance in 2024, but packages it into a more compact, dedicated blood pressure form factor.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.
The company has also been developing a combined "BP Go Rhythm" variant that layers single-lead ECG onto the same finger-cuff design through a partnership with UK biosensing firm B-Secur, and its devices support both Bluetooth and cellular connectivity with a REST API for EHR integration, positioning BP Go as infrastructure for provider-run remote patient monitoring programs rather than just a standalone consumer device.
The clearance lands amid a broader industry shift toward cuffless and optical blood pressure measurement, as device makers look to cut the friction and compliance issues that have long dogged cuff-based home monitoring in chronic care. Notably, Wellvii's announcement didn't include a commercial launch timeline, pricing, or named payer or health-system partnerships, so this reads as a regulatory milestone rather than a go-to-market update for now.
